Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Rating of “Hold” from Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company.

Several equities research analysts recently weighed in on the stock. Wolfe Research cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday. Berenberg Bank cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $44.86 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $83.12. The business has a 50 day simple moving average of $46.61 and a two-hundred day simple moving average of $52.34. The stock has a market capitalization of $3.21 billion, a PE ratio of 3.33 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.50. The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%. On average, research analysts predict that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.